Table 2

 Predicted treatment preferences

ScenarioPercentage of patients preferring a specific option
MethotrexateGoldLeflunomideEtanercept
Base case1.7 (1.2)2.5 (1.4)0.8 (0.8)95.0 (2.0)
All equally effective4.2 (1.8)7.5 (2.4)1.0 (0.8)87.5 (3.0)
All equally effective, co-pay of etanercept increased to $30.005.8 (2.1)10.8 (2.8)3.3 (1.6)80.0 (3.7)